Publication: The effect of teriparatide treatment on the risk of fragility fractures in postmenopausal women with osteoporosis: Results from the asian and latin america fracture observational study (ALAFOS)
dc.contributor.author | Chen, Chung-Hwan | |
dc.contributor.author | Elsalmawy, Abdulaziz H. | |
dc.contributor.author | Ish-Shalom, Sophia | |
dc.contributor.author | Lim, Seung-Jae | |
dc.contributor.author | AlAli, Nadia S. | |
dc.contributor.author | Cunha-Borges, Joao L. | |
dc.contributor.author | Yang, Huilin | |
dc.contributor.author | Casas, Noemi | |
dc.contributor.author | Altan, Lale | |
dc.contributor.author | Belaya, Zhanna | |
dc.contributor.author | Marin, Fernando | |
dc.contributor.author | Moll, Thomas | |
dc.contributor.author | Gurbuz, Sirel | |
dc.contributor.author | Brnabic, Alan | |
dc.contributor.author | Pavo, Imre | |
dc.contributor.author | Florez, Sandra | |
dc.contributor.buuauthor | Altan, Lale | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı | |
dc.contributor.researcherid | AAH-1652-2021 | |
dc.date.accessioned | 2024-06-14T05:56:26Z | |
dc.date.available | 2024-06-14T05:56:26Z | |
dc.date.issued | 2021-08-20 | |
dc.description.abstract | The Asian and Latin America Fracture Observational Study (ALAFOS) is a prospective, observational, single-arm study conducted in 20 countries across Asia, Latin America and the Middle East. ALAFOS evaluated new clinical vertebral and non-vertebral fragility fractures in relation to time on teriparatide, in postmenopausal women with osteoporosis in real-life clinical practice. Clinical fragility fractures, back pain, and health-related quality of life (HRQoL) were recorded in 6-month intervals for <= 24 months during teriparatide treatment and up to 12-months post-treatment. Data were analysed with piecewise exponential regression with inverse probability weighting for time to event outcomes and mixed-model repeated measures for back pain and HRQoL. 3054 postmenopausal women started teriparatide and attended >= one follow-up visit (mean [SD] age 72.5 [10.4] years). The median (95% CI) time to treatment discontinuation was 22.0 months (21.2, 22.8). During the treatment period, 111 patients (3.6%) sustained 126 clinical fractures (2.98 fractures/100 patient-years). Rates of new clinical fragility fractures were significantly decreased during the > 6-12, > 12-18, and > 18-24-month periods, as compared with the first 6 months of treatment (hazard ratio [HR] 0.57; 95% CI 0.37, 0.88; p = 0.012; HR 0.35; 95% CI 0.19, 0.62; p < 0.001; HR 0.43; 95% CI 0.23, 0.83; p = 0.011; respectively). Patients also reported an improvement in back pain and HRQoL (p < 0.001). These results provide data on the real-world effectiveness of teriparatide in the ALAFOS regions and are consistent with other studies showing reduction of fractures after 6 months of teriparatide treatment. These results should be interpreted in the context of the noncontrolled design of this observational study. | |
dc.description.sponsorship | Holly Green, PhD (Eli Lilly and Company) | |
dc.description.sponsorship | Eli Lilly | |
dc.identifier.doi | 10.1007/s00223-021-00895-4 | |
dc.identifier.eissn | 1432-0827 | |
dc.identifier.endpage | 86 | |
dc.identifier.issn | 0171-967X | |
dc.identifier.issue | 1 | |
dc.identifier.startpage | 74 | |
dc.identifier.uri | https://doi.org/10.1007/s00223-021-00895-4 | |
dc.identifier.uri | https://link.springer.com/article/10.1007/s00223-021-00895-4 | |
dc.identifier.uri | https://hdl.handle.net/11452/42181 | |
dc.identifier.volume | 110 | |
dc.identifier.wos | 000686879100001 | |
dc.indexed.wos | WOS.SCI | |
dc.language.iso | en | |
dc.publisher | Springer | |
dc.relation.journal | Calcified Tissue International | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Parathyroid-hormone 1-34 | |
dc.subject | Worldwide prevalence | |
dc.subject | Persistence | |
dc.subject | Guidelines | |
dc.subject | Adherence | |
dc.subject | East | |
dc.subject | Fracture | |
dc.subject | Observational study | |
dc.subject | Osteoporosis | |
dc.subject | Teriparatide | |
dc.subject | Back pain | |
dc.subject | Science & technology | |
dc.subject | Life sciences & biomedicine | |
dc.subject | Endocrinology & metabolism | |
dc.title | The effect of teriparatide treatment on the risk of fragility fractures in postmenopausal women with osteoporosis: Results from the asian and latin america fracture observational study (ALAFOS) | |
dc.type | Article | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1